PPA
CDTX

Parametric Portfolio Associates’s Cidara Therapeutics CDTX Stock Holding History

Parametric Portfolio Associates’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,700
Closed -$69K – 3609
2021
Q2 		$69K Buy
+1,700
New +$71.9K ﹤0.01% 3517
2017
Q3 		– Sell
-602
Closed -$90K – 4027
2017
Q2 		$90K Buy
+602
New +$83.2K ﹤0.01% 3929

Other funds holding CDTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Parametric Portfolio Associates's CDTX Position: Q3 2021 in Review

Parametric Portfolio Associates sold out of Cidara Therapeutics (CDTX) in Q3 2021, closing a stake of 1,700 shares — an estimated $69K sold.

Parametric Portfolio Associates first reported a position in CDTX in Q2 2017 and held it in 2 quarters. The position peaked at $90K in Q2 2017. 50 funds tracked by Wall St. Rank hold CDTX as of Q3 2021.

  • Parametric Portfolio Associates reported no remaining Cidara Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Parametric Portfolio Associates sold 1,700 Cidara Therapeutics shares in Q3 2021, an estimated $69K.
  • Parametric Portfolio Associates first reported a position in Cidara Therapeutics in Q2 2017 and held it in 2 quarters.
  • Parametric Portfolio Associates's Cidara Therapeutics position peaked at $90K in Q2 2017.
  • 50 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q3 2021.

Based on Parametric Portfolio Associates's 13F filing for Q3 2021, filed 15 Nov 2021.